I am not bothered about the conference and if they present or do not present any data. I am talking of the final data and that is when the rubber meets the road.
Too many peeps that claim to be long hoping and praying that something kneecaps Advaxis and it stumbles. With these kinds of long shareholders, who needs shorts and HFT?
they saw 30% stabilization in these end of life patients ..its proving itself in the trials. yet another indicator to go with all the others.its easy to see why talks are geared toward fastest way to market..hard to price a dramatically cheaper, more effective, and easily tolerated cancer treatment for current cancer types for which there is no treatment but adxs..
Market Data 
Markets 
AI
